In a post hoc analysis of six phase III RCTs of patients with pre-existing CVD who received ADT for 12 months mostly, the LHRH antagonist degarelix was associated with a significantly lower risk of cardiac events (arterial embolic/thrombotic events, hemorrhagic/ischemic cerebrovascular conditions, MI, and other ischemic heart disease) or death compared with LHRH agonists within 1 year of treatment (HR 0.44; 95% CI 0.26–0.74; P = 0.002) (61). The gene discussed is GNRH1; the disease is coronary artery disorder.